{"analyses":[{"groupDescription":"Stratified Analysis; Stratification factors: Prior exposure to proteasome inhibitors (naïve versus sensitive), and number of prior lines of therapy (1 versus 2 or 3)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.7","upperLimit":"21.3","value":"15.5"},{"groupId":"OG001","lowerLimit":"0.3","upperLimit":"7.3","value":"2.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"97"}],"units":"Participants"}],"description":"MRD negativity rate is defined as the percentage of participants who have negative MRD by bone marrow aspirate at any time point after randomization and before progression or starting subsequent therapy. MRD negativity was defined at 10\\^-5 threshold (less than one residual myeloma cell per 10\\^5 total nucleated cells) as measured by centralized testing of bone marrow aspirate by Next Generation Sequencing (NGS). MRD positive participants include those of which all tested samples were found to be MRD positive or indeterminate. Participants with missing or unevaluable MRD status were considered as MRD positive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Cycles 1-8: Venetoclax 800 mg orally every day (QD) on Days 1 - 21 plus bortezomib 1.3 mg/m\\^2 subcutaneously or IV on Days 1, 4, 8 \\& 11 and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 \\& 12; Cycles 9 and beyond: Venetoclax 800 mg orally every day (QD) on Days 1 - 35 plus bortezomib 1.3 mg/m\\^2 subcutaneously or IV on Days 1, 8, 15 and 22 and dexamethasone 20 mg orally on Days 1, 2, 8, 9, 15, 16, 22 and 23","id":"OG000","title":"Venetoclax + Bortezomib and Dexamethasone"},{"description":"Cycles 1-8: Placebo (to match venetoclax 100 mg tablet) 800 mg orally every day (QD) on Days 1 - 21 plus bortezomib 1.3 mg/m\\^2 subcutaneously or IV on Days 1, 4, 8 \\& 11 and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 \\& 12; Cycles 9 and beyond: Placebo (to match venetoclax 100 mg tablet) 800 mg orally every day (QD) on Days 1 - 35 plus bortezomib 1.3 mg/m\\^2 subcutaneously or IV on Days 1, 8, 15 and 22 and dexamethasone 20 mg orally on Days 1, 2, 8, 9, 15, 16, 22 \\& 23","id":"OG001","title":"Placebo + Bortezomib and Dexamethasone"}],"paramType":"NUMBER","populationDescription":"Intent-To-Treat (ITT) analysis set: all randomized participants, analyzed by treatment group assignment given at the time of randomization","reportingStatus":"POSTED","timeFrame":"Assessed at Screening; to confirm a stringent Complete Response (sCR) or Complete Response (CR); at 6 months and 12 months post-confirmed CR/sCR","title":"Minimal Residual Disease (MRD) Negativity Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}